Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00263822
Registration number
NCT00263822
Ethics application status
Date submitted
7/12/2005
Date registered
9/12/2005
Date last updated
27/08/2013
Titles & IDs
Public title
Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer
Query!
Scientific title
A Randomized, Multicenter, Phase III Study of Erlotinib Versus Observation in Patients With no Evidence of Disease Progression After First Line, Platinum-Based Chemotherapy For High-Risk Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Query!
Secondary ID [1]
0
0
EORTC-55041
Query!
Secondary ID [2]
0
0
EORTC-55041
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Fallopian Tube Cancer
0
0
Query!
Ovarian Cancer
0
0
Query!
Primary Peritoneal Cavity Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Ovarian and primary peritoneal
Query!
Cancer
0
0
0
0
Query!
Womb (Uterine or endometrial cancer)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - erlotinib hydrochloride
Treatment: Drugs: erlotinib hydrochloride
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-free survival
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Secondary outcome [1]
0
0
Overall survival
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Secondary outcome [2]
0
0
Adverse event profile
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Query!
Secondary outcome [3]
0
0
Quality of life
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Query!
Secondary outcome [4]
0
0
Cutaneous toxicity (rash or acne [papulo-pustular rash])
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Query!
Eligibility
Key inclusion criteria
DISEASE CHARACTERISTICS:
- Histologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube
cancer meeting 1 of the following criteria:
- High-risk stage I disease, as defined by grade 3, aneuploid grade 1 or 2, or
clear cell disease
- Stage II, III, or IV disease
- Completed first-line therapy within the past 6 weeks
- Received a platinum derivative (carboplatin or cisplatin) alone or in combination
with other agents for 6-9 courses
- Must have achieved complete response/no evidence of disease, partial response, or
stabilization of disease after therapy
- No adenocarcinoma of unknown origin
- No known brain metastases or leptomeningeal disease
PATIENT CHARACTERISTICS:
Performance status
- ECOG 0-1
Life expectancy
- Not specified
Hematopoietic
- Platelet count = 100,000/mm^3
- WBC = 2,000/mm^3
Hepatic
- AST and ALT = 2.5 times upper limit of normal (ULN) (= 5 times ULN in patients with
known liver metastases)
- Bilirubin = 1.5 times ULN
- Alkaline phosphatase = 5 times ULN except in patients with known bone metastases
- PT and PTT = 1.5 times ULN
Renal
- Creatinine = 2 times ULN
Cardiovascular
- No myocardial infarction within past 6 months
- No second- or third-degree heart block without pacemaker
Gastrointestinal
- No active peptic ulcer disease
- No gastrointestinal tract disease that would interfere with ability to take oral
medications, affect absorption, or require parenteral nutrition
- No uncontrolled inflammatory bowel disease (e.g., Crohn's disease or ulcerative
colitis)
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No significant dermatologic disease
- No inflammatory changes to the surface of the eye
- No history of allergic reaction to compounds of similar chemical composition as
erlotinib
- No other significant medical condition or neurologic or psychiatric disorder
- No other malignancy within the past 5 years except adequately treated basal cell or
squamous cell skin cancer or cone-biopsied carcinoma in situ of the cervix
- No psychiatric illness or familial, geographic, or social situation that would
preclude study compliance
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No prior therapy targeting epidermal growth factor receptor
- No concurrent immunotherapy
Chemotherapy
- See Disease Characteristics
- See Surgery
- No concurrent chemotherapy
Endocrine therapy
- No concurrent hormonal therapy
Radiotherapy
- No prior radiotherapy unless completed more than 5 years ago AND outside the
abdomen/pelvis
Surgery
- Interval debulking surgery after 3 courses of chemotherapy and second-look surgery at
the end of chemotherapy allowed as per study EORTC-55971/NCIC OV13/Chorus
Other
- No other prior or concurrent investigational agents
- No other concurrent anticancer treatment
- Concurrent participation in study EORTC-55971/NCIC-OV13/Chorus allowed
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2005
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
835
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
Prince of Wales Private Hospital - Randwick
Query!
Recruitment hospital [2]
0
0
Tamworth Base Hospital - Tamworth
Query!
Recruitment hospital [3]
0
0
Manning Base Hospital - Taree
Query!
Recruitment hospital [4]
0
0
Newcastle Mater Misericordiae Hospital - Waratah
Query!
Recruitment hospital [5]
0
0
Royal Brisbane and Women's Hospital - Brisbane
Query!
Recruitment hospital [6]
0
0
Royal Women's Hospital - Carlton
Query!
Recruitment hospital [7]
0
0
Frankston Hospital - Frankston
Query!
Recruitment hospital [8]
0
0
Murray Valley Private Hospital and Cancer Treatment Centre - Wodonga
Query!
Recruitment hospital [9]
0
0
Sir Charles Gairdner Hospital - Nedlands - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [2]
0
0
2340 - Tamworth
Query!
Recruitment postcode(s) [3]
0
0
2430 - Taree
Query!
Recruitment postcode(s) [4]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [5]
0
0
4029 - Brisbane
Query!
Recruitment postcode(s) [6]
0
0
3053 - Carlton
Query!
Recruitment postcode(s) [7]
0
0
3199 - Frankston
Query!
Recruitment postcode(s) [8]
0
0
3690 - Wodonga
Query!
Recruitment postcode(s) [9]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
Austria
Query!
State/province [1]
0
0
Klagenfurt
Query!
Country [2]
0
0
Austria
Query!
State/province [2]
0
0
Kufstein
Query!
Country [3]
0
0
France
Query!
State/province [3]
0
0
Amilly
Query!
Country [4]
0
0
France
Query!
State/province [4]
0
0
Aulnay Sous Bois
Query!
Country [5]
0
0
France
Query!
State/province [5]
0
0
Besancon
Query!
Country [6]
0
0
France
Query!
State/province [6]
0
0
Bordeaux
Query!
Country [7]
0
0
France
Query!
State/province [7]
0
0
Boucher
Query!
Country [8]
0
0
France
Query!
State/province [8]
0
0
Caen
Query!
Country [9]
0
0
France
Query!
State/province [9]
0
0
Chambery
Query!
Country [10]
0
0
France
Query!
State/province [10]
0
0
Clermont-Ferrand
Query!
Country [11]
0
0
France
Query!
State/province [11]
0
0
Colmar
Query!
Country [12]
0
0
France
Query!
State/province [12]
0
0
Dax
Query!
Country [13]
0
0
France
Query!
State/province [13]
0
0
Evreux
Query!
Country [14]
0
0
France
Query!
State/province [14]
0
0
Gap
Query!
Country [15]
0
0
France
Query!
State/province [15]
0
0
La Roche Sur Yon
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Le Mans
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Lorient
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Lyon
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Marseille
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Mont-de-Marsan
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Montbeliard
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Montlucon
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Montpellier
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Paris
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Perigueux
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Pierre Benite
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Poitiers
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Reims
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Rennes
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Saint Brieuc
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Strasbourg
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Tours
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Valence
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Vandoeuvre-les-Nancy
Query!
Country [35]
0
0
Italy
Query!
State/province [35]
0
0
Aviano
Query!
Country [36]
0
0
Italy
Query!
State/province [36]
0
0
Como
Query!
Country [37]
0
0
Italy
Query!
State/province [37]
0
0
Latina
Query!
Country [38]
0
0
Italy
Query!
State/province [38]
0
0
Milan
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
Monza
Query!
Country [40]
0
0
Italy
Query!
State/province [40]
0
0
Turin
Query!
Country [41]
0
0
Italy
Query!
State/province [41]
0
0
Varese
Query!
Country [42]
0
0
Netherlands
Query!
State/province [42]
0
0
Amsterdam
Query!
Country [43]
0
0
Netherlands
Query!
State/province [43]
0
0
Groningen
Query!
Country [44]
0
0
Netherlands
Query!
State/province [44]
0
0
Leiden
Query!
Country [45]
0
0
Netherlands
Query!
State/province [45]
0
0
Nijmegen
Query!
Country [46]
0
0
Netherlands
Query!
State/province [46]
0
0
Rotterdam
Query!
Country [47]
0
0
Portugal
Query!
State/province [47]
0
0
Coimbra
Query!
Country [48]
0
0
Spain
Query!
State/province [48]
0
0
Barcelona
Query!
Country [49]
0
0
Spain
Query!
State/province [49]
0
0
Madrid
Query!
Country [50]
0
0
Spain
Query!
State/province [50]
0
0
Oviedo
Query!
Country [51]
0
0
Spain
Query!
State/province [51]
0
0
Valencia
Query!
Country [52]
0
0
United Kingdom
Query!
State/province [52]
0
0
England
Query!
Country [53]
0
0
United Kingdom
Query!
State/province [53]
0
0
Scotland
Query!
Country [54]
0
0
United Kingdom
Query!
State/province [54]
0
0
Wales
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
European Organisation for Research and Treatment of Cancer - EORTC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Sometimes after treatment, the tumor may not need additional
treatment until it progresses. In this case, observation may be sufficient. It is not yet
known whether erlotinib is more effective than observation after first-line chemotherapy in
treating patients with ovarian cancer, peritoneal cancer, or fallopian tube cancer.
PURPOSE: This randomized phase III trial is studying erlotinib to see how well it works
compared to observation in treating patients who have undergone first-line chemotherapy for
ovarian cancer, peritoneal cancer, or fallopian tube cancer.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00263822
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Antonio Jimeno
Query!
Address
0
0
Hospital Universitario 12 de Octubre
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00263822
Download to PDF